Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial.
Mitochondrial dysfunction plays a major role in the pathogenesis of Parkinson disease (PD). Creatine (Cr) is an ergogenic compound that exerts neuroprotective effects in animal models of PD. We conducted a 2-year placebo-controlled randomized clinical trial on the effect of Cr in 60 patients with PD. Cr improved patient mood and led to a smaller dose increase of dopaminergic therapy but had no effect on overall Unified Parkinson's Disease Rating Scale scores or dopamine transporter SPECT.
Bender
A
A
Department of Neurology, Klinikum Grosshadern, Klinikum Grosshadern, University of Munich, Germany.
Koch
W
W
Elstner
M
M
Schombacher
Y
Y
Bender
J
J
Moeschl
M
M
Gekeler
F
F
Müller-Myhsok
B
B
Gasser
T
T
Tatsch
K
K
Klopstock
T
T
D000284:Administration, Oral; D001921:Brain / Q000000981:diagnostic imaging* / Q000187:drug effects*; D003401:Creatine / Q000008:administration & dosage*; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D010865:Pilot Projects; D015990:Placebo Effect; D011877:Radionuclide Imaging; D016896:Treatment Outcome
D003401:Creatine